MX2022000302A - Moleculas de union que inhiben el crecimiento del cancer. - Google Patents

Moleculas de union que inhiben el crecimiento del cancer.

Info

Publication number
MX2022000302A
MX2022000302A MX2022000302A MX2022000302A MX2022000302A MX 2022000302 A MX2022000302 A MX 2022000302A MX 2022000302 A MX2022000302 A MX 2022000302A MX 2022000302 A MX2022000302 A MX 2022000302A MX 2022000302 A MX2022000302 A MX 2022000302A
Authority
MX
Mexico
Prior art keywords
binding molecules
cancer growth
inhibit cancer
antibodies
membrane associated
Prior art date
Application number
MX2022000302A
Other languages
English (en)
Inventor
Mark Throsby
Johannes Carolus Clevers
Ton Logtenberg
Robert Gerhardus Jacob Vries
Eduard Batlle
Bram Herpers
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2022000302A publication Critical patent/MX2022000302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La invención proporciona medios y métodos para inhibir el crecimiento de un cáncer. Los medios, en algunas modalidades, comprenden proteínas y anticuerpos que unen una parte extracelular de un miembro asociado a la membrana de la familia del receptor de factor de crecimiento epidérmico (EGF) y una parte extracelular de un miembro asociado a la membrana de una ruta de señalización de WNT. Además, se proporcionan diversas células y ensayos que son útiles para la producción de las proteínas, anticuerpos y células.
MX2022000302A 2015-10-23 2018-04-23 Moleculas de union que inhiben el crecimiento del cancer. MX2022000302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
EP16168647 2016-05-06

Publications (1)

Publication Number Publication Date
MX2022000302A true MX2022000302A (es) 2022-02-03

Family

ID=57190021

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004988A MX2018004988A (es) 2015-10-23 2016-10-21 Moleculas de union que inhibe el crecimiento de cancer.
MX2022000302A MX2022000302A (es) 2015-10-23 2018-04-23 Moleculas de union que inhiben el crecimiento del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018004988A MX2018004988A (es) 2015-10-23 2016-10-21 Moleculas de union que inhibe el crecimiento de cancer.

Country Status (26)

Country Link
US (1) US11939394B2 (es)
EP (2) EP3365373B1 (es)
JP (3) JP7296728B2 (es)
KR (1) KR20180100305A (es)
CN (2) CN115925944A (es)
AU (2) AU2016340764B2 (es)
BR (1) BR112018008068A2 (es)
CA (1) CA3002957A1 (es)
CY (1) CY1124108T1 (es)
DK (1) DK3365373T3 (es)
EA (1) EA201890866A1 (es)
ES (1) ES2865482T3 (es)
HK (1) HK1253914A1 (es)
HR (1) HRP20210483T1 (es)
HU (1) HUE055222T2 (es)
LT (1) LT3365373T (es)
MA (2) MA45517B1 (es)
MD (1) MD3365373T2 (es)
MX (2) MX2018004988A (es)
NZ (1) NZ742290A (es)
PL (1) PL3365373T3 (es)
RS (1) RS61800B1 (es)
SG (1) SG11201803359VA (es)
SI (1) SI3365373T1 (es)
WO (1) WO2017069628A2 (es)
ZA (1) ZA201802758B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
EP3126397B1 (en) * 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
ES2865482T3 (es) 2015-10-23 2021-10-15 Merus Nv Moléculas de unión que inhiben el crecimiento del cáncer
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
CN110325210A (zh) * 2017-01-11 2019-10-11 小利兰·斯坦福大学托管委员会 Rspo替代物分子
AU2018211985A1 (en) * 2017-01-26 2019-07-18 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
CN111094350A (zh) * 2017-07-06 2020-05-01 美勒斯公司 调节由细胞表达的生物活性的抗体
WO2019009727A1 (en) * 2017-07-06 2019-01-10 Merus N.V. ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES
CN111094351A (zh) 2017-08-09 2020-05-01 美勒斯公司 结合EGFR和cMET的抗体
CA3094318A1 (en) * 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
JP2021530223A (ja) * 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
EP3886905A4 (en) * 2018-12-27 2022-08-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. BISPECIFIC ANTIBODY FOR MEMBRANE REMOVAL OF TARGET RECEPTORS
US20220380440A1 (en) 2018-12-31 2022-12-01 Merus N.V. Truncated multivalent multimers
CA3124768A1 (en) * 2018-12-31 2020-07-09 Merus N.V. Mixed binding domains
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CN113840842A (zh) 2019-02-26 2021-12-24 詹森生物科技公司 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
TW202102544A (zh) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EP4017879A2 (en) 2019-08-19 2022-06-29 Merus N.V. Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor
MX2022005241A (es) * 2019-11-01 2022-07-27 Univ California Degradacion de proteinas de superficie usando agente de union biespecifico.
EP4114854A1 (en) * 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
EP4139357A1 (en) * 2020-04-24 2023-03-01 Merus N.V. Treatment of cancers with an antibody that binds lgr5 and egfr
AU2021291235A1 (en) * 2020-06-18 2022-12-22 Umc Utrecht Holding B.V. Screening method for effective target - E3 ligase combinations
CN113862326A (zh) * 2020-09-08 2021-12-31 复旦大学 KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用
IL303633A (en) 2020-12-15 2023-08-01 Merus Nv Cancer treatment with an antibody that binds LGR5 and EGFR
CN116801907A (zh) * 2020-12-18 2023-09-22 美勒斯公司 抗体组合物
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
AU2022359551A1 (en) 2021-10-06 2024-04-11 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
CN116082510B (zh) * 2023-03-07 2023-12-05 四川尚锐生物医药有限公司 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1993002190A1 (en) 1991-07-15 1993-02-04 The Wellcome Foundation Limited Production of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 Missel Gmbh & Co E Trägersystem für Bade-, Dusch- oder Whirlwannen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2000063403A2 (en) 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
DE29915950U1 (de) 1999-09-10 1999-12-30 Cmw Automation Gmbh Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ES2344070T3 (es) 2001-07-04 2010-08-17 Chromagenics B.V. Secuencias de adn con actividad anti-represora.
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
EP1510943A4 (en) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc INTERACTION PREDICTION DEVICE
WO2004061104A2 (en) 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1853309A4 (en) 2005-02-23 2008-10-22 Merrimack Pharmaceuticals Inc BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
AU2008270972B2 (en) 2007-07-02 2013-10-24 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2009051974A1 (en) 2007-10-17 2009-04-23 Nuvelo, Inc. Antibodes to cll-1
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
US9404928B2 (en) 2008-02-05 2016-08-02 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
ES2535723T3 (es) 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
CN102365296A (zh) 2009-01-26 2012-02-29 根马布股份公司 用于生成抗体混合物的方法
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
ES2728942T3 (es) 2010-02-08 2019-10-29 Regeneron Pharma Cadena ligera común de ratón
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
PE20140230A1 (es) 2010-08-20 2014-02-26 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
MX2013009732A (es) 2011-02-24 2013-12-06 Merrimack Pharmaceuticals Inc Terapias de combinacion comprendiendo agentes anti-erbb3.
BR112013022887A2 (pt) 2011-03-15 2016-12-06 Merrimack Pharmaceuticals Inc superação de resistência a inibidores de via de erbb
CN107840894A (zh) 2011-03-25 2018-03-27 格兰马克药品股份有限公司 异二聚体免疫球蛋白
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
DK2707391T3 (en) 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
JPWO2012176779A1 (ja) 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
WO2013012747A1 (en) * 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EA201791393A3 (ru) 2011-09-30 2018-03-30 Ридженерон Фармасьютикалз, Инк. Антитела к erbb3 и их применение
CA2856297C (en) 2011-11-23 2023-10-17 Medimmune, Llc Binding molecules specific for her3 and uses thereof
CA2857939A1 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
JP6243345B2 (ja) 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
JP6231503B2 (ja) 2012-03-09 2017-11-15 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ｐＨセンサー
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20230091201A (ko) 2012-04-20 2023-06-22 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
TR201815768T4 (tr) 2012-09-27 2018-11-21 Merus Nv T hücre bağlayıcılar olarak bispesifik IgG antikorları.
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
JP6423357B2 (ja) 2012-11-21 2018-11-14 ヤンセン バイオテツク，インコーポレーテツド 二重特異性ＥＧＦＲ／ｃ−Ｍｅｔ抗体
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
BR112015023074A2 (pt) * 2013-03-14 2017-11-21 Oncomed Pharm Inc agentes de ligação-met e uso dos mesmos
EP2981828A1 (en) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
CN106459212B (zh) 2014-02-28 2021-07-13 美勒斯公司 结合erbb-2和erbb-3的抗体
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
MY178160A (en) * 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
ES2865482T3 (es) 2015-10-23 2021-10-15 Merus Nv Moléculas de unión que inhiben el crecimiento del cáncer
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2018182420A1 (en) 2017-03-31 2018-10-04 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
ES2951864T3 (es) 2017-05-17 2023-10-25 Merus Nv Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama
CN111094351A (zh) 2017-08-09 2020-05-01 美勒斯公司 结合EGFR和cMET的抗体
SG11202106764YA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof

Also Published As

Publication number Publication date
HK1253914A1 (zh) 2019-07-05
ES2865482T3 (es) 2021-10-15
CA3002957A1 (en) 2017-04-27
ZA201802758B (en) 2020-08-26
CN108602888A (zh) 2018-09-28
MD3365373T2 (ro) 2021-08-31
EP3912998A3 (en) 2022-02-23
PL3365373T3 (pl) 2021-08-23
HRP20210483T1 (hr) 2021-07-09
JP7296728B2 (ja) 2023-06-23
EA201890866A1 (ru) 2018-09-28
DK3365373T3 (da) 2021-04-06
CN108602888B (zh) 2022-10-04
EP3365373B1 (en) 2021-03-10
MX2018004988A (es) 2018-11-09
RS61800B1 (sr) 2021-06-30
BR112018008068A2 (pt) 2018-11-13
WO2017069628A3 (en) 2017-09-08
US11939394B2 (en) 2024-03-26
KR20180100305A (ko) 2018-09-10
JP2019500405A (ja) 2019-01-10
HUE055222T2 (hu) 2021-11-29
JP2024023445A (ja) 2024-02-21
US20180312604A1 (en) 2018-11-01
MA45517B1 (fr) 2021-04-30
SG11201803359VA (en) 2018-05-30
CY1124108T1 (el) 2022-05-27
AU2016340764A1 (en) 2018-05-17
WO2017069628A2 (en) 2017-04-27
AU2016340764B2 (en) 2023-06-01
EP3912998A2 (en) 2021-11-24
LT3365373T (lt) 2021-05-25
MA54760A (fr) 2022-04-13
AU2023222928A1 (en) 2023-09-21
NZ742290A (en) 2019-11-29
EP3365373A2 (en) 2018-08-29
WO2017069628A9 (en) 2017-10-26
SI3365373T1 (sl) 2021-08-31
CN115925944A (zh) 2023-04-07
JP2023008754A (ja) 2023-01-19
MA45517A (fr) 2018-08-29

Similar Documents

Publication Publication Date Title
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
HK1253005A1 (zh) 前列腺特異性膜抗原結合iii型纖連蛋白結構域
IL266800A (en) Prostate-specific membrane antigen-binding protein
BR112017020054A2 (pt) anticorpos para icos
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
BR112014019579A2 (pt) Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
MX2017006530A (es) Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen.
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
NZ725568A (en) Modified j-chain
JO3775B1 (ar) جزيئات رابطة لليمفو بويتين اللحمية بالغدة الصعترية أو الثيمية (tslp) وطرق لاستخدام تلك الجزيئات
EP3291836A4 (en) Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
IN2014DN05885A (es)
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
MX2016012273A (es) Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
MX2018004005A (es) Ensayo de potencia celular.
MX2017005310A (es) Metodos basados en proximidad para seleccion de parejas para ligadura.
NZ731491A (en) Cd83 binding proteins and uses thereof
MX2015015448A (es) Ensayo de internalizacion del receptor del gusto.
EA201991922A1 (ru) Сконструированные полипептиды, связывающие трансферриновый рецептор